Sorrento Therapeutics Inc., of San Diego, received a Small Business Innovation Research phase I grant from the National Heart, Lung, and Blood Institute to advance an immunotherapy targeting WNT1-inducible signaling protein-1 for the potential treatment of idiopathic pulmonary fibrosis.